Acrivon Therapeutics has advanced ACR-2316 into the randomized dose-expansion portion of its Phase 1/2 study after observing early tumor shrinkage, partial responses and prolonged disease control across several advanced solid tumors. The oral dual WEE1 and PKMYT1 inhibitor will now be evaluated at two dose levels across selected lung, gynecological and gastrointestinal cancers to identify the regimen with the strongest overall benefit-risk profile.
The most notable early signal came from seven efficacy-evaluable patients with small cell lung cancer, squamous non-small cell lung cancer or lung adenocarcinoma. Six achieved either a partial response or stable disease, producing an 86% disease control rate, while three heavily pretreated patients remained on therapy for more than one year. These findings suggest biological activity in tumor types that Acrivon Therapeutics says have not historically demonstrated sensitivity to single-agent WEE1 or PKMYT1 inhibitors.
The evidence remains preliminary. Seven evaluable lung cancer patients cannot establish a dependable response rate, and the ongoing open-label trial does not include a control group capable of showing how outcomes compare with existing treatment or the natural course of disease. The randomized expansion is therefore an important transition from identifying an early activity signal to determining whether that signal can be reproduced across a larger and more systematically selected population.
Randomized testing will compare two weekly ACR-2316 doses across six cancer groups
Acrivon Therapeutics selected oral doses of 120 milligrams and 160 milligrams once daily, administered for three consecutive days followed by four days without treatment. Patients will be divided into lung cancer and non-lung cancer groups before being randomized equally between the two candidate doses. The study is intended to identify the recommended Phase 2 dose rather than automatically advancing the highest tolerated amount.
The expansion will include patients with small cell lung cancer, squamous non-small cell lung cancer, lung adenocarcinoma, endometrial cancer, cervical cancer and cancer of the esophagogastric junction. Acrivon Therapeutics selected these populations using its AP3 phosphoproteomics platform, which analyzes intracellular signaling networks to identify tumor types that may be particularly vulnerable to the drug’s mechanism.
Potential biomarker features include loss or mutation of TP53 or FBXW7, amplification or overexpression of CCNE1 or CCNB1, and human papillomavirus positivity in cervical cancer. These alterations can disrupt cell-cycle regulation or increase dependence on checkpoint pathways that cancer cells use to survive DNA damage and uncontrolled replication.
The randomized dose comparison follows the principles of the United States Food and Drug Administration’s Project Optimus initiative. The program encourages oncology developers to select doses using the combined evidence on efficacy, safety, tolerability, pharmacokinetics and pharmacodynamic activity rather than relying primarily on the maximum tolerated dose. Randomized evaluation can reveal whether a lower dose preserves antitumor activity while reducing adverse events and treatment interruptions.
That distinction may be especially relevant for targeted cancer medicines administered for extended periods. A dose that produces greater short-term drug exposure may not provide greater clinical benefit if toxicity forces repeated reductions, missed treatments or permanent discontinuation.
ACR-2316 is designed to disrupt several cell-cycle escape routes simultaneously
WEE1 and PKMYT1 are kinases involved in controlling when cells enter mitosis, the stage during which duplicated chromosomes are separated before cell division. Cancer cells with damaged DNA can depend heavily on these checkpoints to delay division long enough to repair damage and remain alive.
ACR-2316 is designed to inhibit both WEE1 and PKMYT1 while activating the downstream cell-cycle regulators CDK1, CDK2 and PLK1. Acrivon Therapeutics developed the compound using its AP3 platform to create a coordinated pathway effect intended to force cancer cells with substantial replication stress into premature division and programmed cell death.
The dual-target design is intended to overcome resistance mechanisms that can limit medicines focused only on WEE1 or PKMYT1. Whether the broader pathway activity produces greater efficacy without creating excessive toxicity is one of the central questions the clinical program must answer.
Thirty-five patients received ACR-2316 across six dose levels ranging from 30 milligrams to 240 milligrams in two weekly schedules during dose escalation. Tumor shrinkage and durable clinical benefit were observed among patients treated at doses of at least 120 milligrams, including partial responses in lung and endometrial cancers.
Acrivon Therapeutics also evaluated a biweekly schedule involving three treatment days followed by 11 days without dosing but decided not to advance that regimen. The company instead selected the three-days-on, four-days-off schedule for randomized expansion, indicating that weekly exposure appeared to offer a more suitable balance of activity and tolerability.
The 86% disease control rate is encouraging but highly sensitive to each patient
Among the seven evaluable lung cancer patients, two achieved partial responses, four had stable disease and one experienced progressive disease. The patients had received a median of three previous systemic treatment lines, placing the observed activity in a heavily pretreated setting where durable control can be difficult to achieve.
The three patients continuing treatment beyond one year provide the strongest indication that the responses may be clinically meaningful rather than brief radiographic fluctuations. However, Acrivon Therapeutics has not yet provided enough patient-level information to determine the depth and duration of every response, the time required for tumors to shrink or whether outcomes differed between the 120-milligram and 160-milligram doses.
The small cohort also makes percentages appear more precise than the underlying evidence supports. One additional case of progression would materially lower the disease control rate, while one additional response would raise the apparent response rate substantially.
The expansion must show whether antitumor activity is consistent within individual cancer types rather than driven by isolated responders distributed across several diagnoses. Small cell lung cancer, squamous non-small cell lung cancer and lung adenocarcinoma have distinct biological characteristics and treatment landscapes, even though they are grouped together in the initial seven-patient analysis.
Patient selection will be another major test. The value of Acrivon Therapeutics’ AP3 strategy depends on whether the identified molecular and pathway features prospectively enrich the trial for patients whose tumors genuinely respond to ACR-2316.
Transient neutropenia remains the main reported treatment-related safety concern
The 120-milligram and 160-milligram doses were described as well tolerated during dose escalation. Acrivon Therapeutics reported no Grade 4 or higher treatment-related adverse events at the selected schedule, while Grade 3 treatment-related events were primarily transient hematological abnormalities, particularly neutropenia.
Neutropenia reflects a reduction in infection-fighting white blood cells and is a known concern for medicines that disrupt rapidly dividing cells. The clinical significance will depend on its frequency, duration, association with infection and whether patients require growth-factor support, dose interruptions or reductions.
The company highlighted a notable absence of substantial non-hematological treatment-related adverse events in the initial study. That could differentiate ACR-2316 from other cell-cycle inhibitors if confirmed across more patients, since gastrointestinal toxicity, fatigue and other systemic effects can limit long-term dosing.
The randomized comparison should provide a clearer view of whether the 160-milligram dose produces greater activity than 120 milligrams and whether any additional benefit justifies higher toxicity or a greater need for treatment modifications.
Acrivon’s limited market value shows how much rests on the coming expansion data
Acrivon Therapeutics had $97.7 million in cash, equivalents and marketable securities at March 31, 2026, supplemented by $7.3 million from a subsequent equity financing. Management previously projected that those resources would support operations into the third quarter of 2027 and through several planned clinical milestones. The company reported a first-quarter net loss of $19 million, including $15.2 million in research and development expenses.
The financing runway gives Acrivon Therapeutics time to conduct the randomized expansion, but the company remains dependent on clinical success and future capital raising because it has no approved products or commercial revenue.
Acrivon Therapeutics shares traded near $1.60 during the August 5 session, up approximately 2.6%, with a market capitalization of roughly $62 million. The muted response suggests investors may view the expansion as constructive while waiting for larger, dose-specific efficacy results before assigning substantial additional value to the program. That interpretation is an inference from the trading pattern rather than a confirmed explanation from market participants.
ACR-2316 has now produced enough early evidence to justify broader testing, particularly because the durable lung cancer cases emerged in heavily pretreated patients. The randomized expansion must determine whether those results represent repeatable drug activity, whether AP3 can reliably identify responsive tumors and which weekly dose offers the strongest path into later-stage development.
